In patients with Zollinger-Ellison Syndrome the level of gastric acid is elevated. This
increased level of gastric acid is what causes the symptoms of the disease. Certain types of
medication can control the secretion of gastric acid. In this study there are details on how
drugs known as antihistamines (H2 receptor antagonists) can control the levels of gastric
The study describes; which patients are candidates for this research, what to do prior to
initiating treatment, and the appropriate dose of antihistamine to be given.
Initial doses of the medication will be given intravenously (injected through a vein) and
later doses will be administered orally (by mouth).
By following the procedure, researchers will be able to determine if there is a more
effective route of drug administration, as well as the effectiveness of antihistamines in
patients treated surgically for Zollinger-Ellison pancreatic tumors with mildly elevated
gastric acid levels.
This protocol describes the use of histamine H2-receptor antagonists to control gastric acid
hypersecretion in patients with Zollinger-Ellison syndrome. It details which patients will
be considered for treatment with these agents, the pretreatment procedures and the
procedures to be followed in establishing the proper intravenous dose of histamine
H2-receptor antagonist. It also details the procedure to be used to establish a safe and
effective oral long-term maintenance dose of either cimetidine, ranitidine, nizatidine, or
famotidine. By following these procedures it will be possible to evaluate the effectiveness
of intravenous histamine H2 therapy if it is determined this is important for antisecretory
control during periods when patients cannot take oral gastric antisecretory agents. It will
also be possible to evaluate the effectiveness of histamine H2-receptor in patients with
Zollinger-Ellison syndrome after successful gastrinoma resection who continue to have mild
- INCLUSION CRITERIA:
Basal gastric acid secretion of greater than 15 mEq/hr (normal less than 10) or greater
than 5 mEq/hr if they have had a previous gastric resection, a fasting plasma
concentration of immunoreactive gastrin of greater than 100 pg/ml (normal less than 100),
a positive secretin provocative tests or histological diagnosis of gastrinoma.